Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Roche”

Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic MelanomaCompleted
NCT02583516Phase 2Updated Feb 17, 2020
Sponsor: Grupo Español Multidisciplinar de Melanoma
Melanoma
Spain
Tocilizumab in Patients With Schnitzler's SyndromeCompleted
NCT03046381Phase 2Updated Feb 17, 2020
Sponsor: Karoline Krause
Schnitzler's Syndrome
Germany
A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid TumorsCompleted
NCT02650713Phase 1Updated Feb 12, 2020
Sponsor: Hoffmann-La Roche
Solid Tumors
United States, Canada, Denmark, France, Italy +2 more
Study to Describe Real World Drug Retention Rate of the Tocilizumab at One YearCompleted
NCT02608112N/AUpdated Feb 11, 2020
Sponsor: Hoffmann-La Roche
Rheumatoid Arthritis
France
A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung CancerCompleted
NCT03155009Phase 2Updated Feb 10, 2020
Sponsor: Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung
France
A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic LeukemiaCompleted
NCT02071225Phase 2Updated Feb 7, 2020
Sponsor: Hoffmann-La Roche
Chronic Lymphocytic Leukemia
Spain
Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple MyelomaCompleted
NCT03068351Phase 1Updated Feb 7, 2020
Sponsor: Hoffmann-La Roche
Multiple Myeloma
United States, Australia, United Kingdom
An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA)Completed
NCT01791153Phase 3Updated Feb 6, 2020
Sponsor: Hoffmann-La Roche
Giant Cell Arteritis
United States, Belgium, Canada, Denmark, France +9 more
Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast CancerCompleted
NCT02605915Phase 1Updated Feb 5, 2020
Sponsor: Hoffmann-La Roche
HER2-Positive Metastatic Breast Cancer · HER2-Negative Metastatic Breast Cancer · Locally Advanced or Early Breast Cancer
United States
Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric CancerWithdrawn
NCT03818997Phase 2Updated Feb 5, 2020
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Esophageal Cancer · Biliary Tract Cancer · GastroEsophageal Cancer · Hepatobiliary Neoplasm
A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha TherapyTerminated
NCT03001219Phase 2Updated Jan 29, 2020
Sponsor: Hoffmann-La Roche
Rheumatoid Arthritis
United States, Argentina, Austria, Colombia, Germany +6 more
A Study of Obinutuzumab to Evaluate Safety and Tolerability in Hypersensitized Adult Participants With End Stage Renal Disease Awaiting TransplantationCompleted
NCT02586051Phase 1Updated Jan 29, 2020
Sponsor: Hoffmann-La Roche
Kidney Failure, Chronic
United States
Is the Concentration of Anti-Muellerian Hormon (AMH) Depending on the Menstrual Cycle?Completed
NCT03398603N/AUpdated Jan 28, 2020
Sponsor: University Hospital, Basel, Switzerland
Ovarian Failure
Switzerland
A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic DermatitisCompleted
NCT02465606Phase 2Updated Jan 27, 2020
Sponsor: Hoffmann-La Roche
Atopic Dermatitis
United States, Canada
A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent.Completed
NCT00353522Phase 2Updated Jan 27, 2020
Sponsor: Hoffmann-La Roche
Coronary Heart Disease
United States, Germany
A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell LymphomaCompleted
NCT02220842Phase 1Updated Jan 27, 2020
Sponsor: Hoffmann-La Roche
Lymphoma
United States, France, Germany, Italy, United Kingdom
A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid TumorsCompleted
NCT02350673Phase 1Updated Jan 18, 2020
Sponsor: Hoffmann-La Roche
Solid Tumors
United States, Canada, Denmark, Netherlands, Spain +1 more
8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast CancerCompleted
NCT01935492Phase 3Updated Jan 18, 2020
Sponsor: Borstkanker Onderzoek Groep
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast · Metastatic Breast Cancer
Netherlands
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)Completed
NCT01059630Phase 3Updated Jan 13, 2020
Sponsor: Genentech, Inc.
Non-Hodgkin's Lymphoma
United States, Austria, Belgium, Canada, Czechia +9 more
A Study to Investigate the Effect of RO7049389 on the Pharmacokinetics of Pitavastatin in Healthy VolunteersCompleted
NCT03717064Phase 1Updated Jan 10, 2020
Sponsor: Hoffmann-La Roche
Healthy Volunteers
United States
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)Completed
NCT01118234Phase 3Updated Jan 9, 2020
Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie
Chronic Lymphocytic Leukemia
Austria, Czechia, Slovakia
Efficacy of Docetaxel, Capecitabine, Cisplatin, and Bevacizumab in Patients With Unresectable Advanced Gastric CancerCompleted
NCT01471470Phase 2Updated Jan 7, 2020
Sponsor: Asan Medical Center
Advanced Gastric Cancer
South Korea
Trastuzumab in Combination With Capecitabine and Oxaliplatin(XELOX) in Patients With Advanced Gastric Cancer(AGC): Her+XELOXCompleted
NCT01396707Phase 2Updated Jan 7, 2020
Sponsor: Asan Medical Center
Metastatic or Recurrent Gastric Adenocarcinoma · Her-2 Positive Gastric Cancer
South Korea
A Study to Observe Treatment Patterns and Outcomes in Participants in Saudi Arabia With Human Epidermal Growth Factor Receptor 2 (HER2-Positive) Unresectable Locally Advanced or Metastatic Breast Cancer (LA/mBC)Terminated
NCT02611310N/AUpdated Jan 7, 2020
Sponsor: Hoffmann-La Roche
Metastatic Breast Cancer
Saudi Arabia
An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic MelanomaCompleted
NCT01898585Phase 4Updated Jan 7, 2020
Sponsor: Hoffmann-La Roche
Malignant Melanoma
South Africa

Previous page Next page